GlassScriptPhysician profile
Gina C Bird
NPI 1902813454
$1,583.03
in general payments reported to CMS, 2019-2025
16 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.45 · 2022: $74.66 · 2023: $662 · 2024: $560 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.68 |
| Education | $382.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $414.61 | 2023-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $212.22 | 2023-2024 | |
| Amgen INC. | $186.36 | 2023-2024 | Otezla |
| Abbvie INC. | $144.17 | 2022-2025 | |
| Ucb, INC. | $108.79 | 2022-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $102.46 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $77.22 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $71.13 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $54.60 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $49.20 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $47.40 | 2023 | |
| Merz Pharmaceuticals, LLC | $29.74 | 2024 | Xeomin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.20 | 2024 | Spevigo |
| Genzyme Corporation | $23.11 | 2023 | |
| Incyte Corporation | $19.40 | 2023 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $15.42 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.